Ohio State Law Journal
The U.S. Food and Drug Administration’s (FDA) policies have been a battleground for litigation about First Amendment protections for commercial speech. In the last five years, the FDA’s position that “off-label” promotion of approved prescription drugs—when a manufacturer promotes a drug for a use for which the FDA has not approved it—leads to violations of the Federal Food, Drug, and Cosmetic Act has been subject to successful legal challenges. Although the merits of these off-label promotion decisions are well traversed in the literature, this Article explores the potential indirect consequences of recently-recognized protections for off-label promotion. This Article demonstrates that—as suggested in the dissenting opinion in United States v. Caronia, a high-profile 2012 case regarding off-label promotion—protections for off-label promotion might affect the FDA’s decision-making in areas other than drug promotion, and analyzes precisely what those effects could be in light of the FDA’s current statutory authority.
Patricia J. Zettler, The Indirect Consequences of Expanded Off-Label Promotion, 78 Ohio St. L.J. 1053 (2017).
Institutional Repository Citation
Zettler, Patricia J., "The Indirect Consequences of Expanded Off-Label Promotion" (2017). Faculty Publications By Year. 2600.
Administrative Law Commons, Chemicals and Drugs Commons, Food and Drug Law Commons, Health Law and Policy Commons, Health Policy Commons, Legal Studies Commons, Other Public Health Commons, Pharmacy Administration, Policy and Regulation Commons